Welcome to our dedicated page for PHARMAGREEN BIOTECH news (Ticker: PHBI), a resource for investors and traders seeking the latest updates and insights on PHARMAGREEN BIOTECH stock.
Pharmagreen Biotech Inc. is a biotech sciences solutions company based in Coquitlam, Canada, specializing in producing starter plantlets for the CBD hemp and medical cannabis industries. The company is focused on developing organic formulations based on mushrooms and therapeutic plants, expanding through white labeling services and industry mergers/acquisitions. Pharmagreen's innovative approach includes nutraceutical products using plant genetics technology to research and create supplements for various health conditions.
The company's major achievement includes being approved for online sales via Amazon's e-commerce platform for their MaxGenomicTM Supplement and securing the use of SierraSil® minerals in their formulations. Pharmagreen is also working on developing pre-workout formulas, gummy products, and looking to achieve positive cash flow by year-end.
Pharmagreen Biotech (OTC PINKS: PHBI) has announced significant revenue potential from its new project focused on producing Live Rosin, a high-quality cannabis concentrate. CEO Peter Wojcik detailed the company's proprietary extraction technique and Standard Organic Non-Spray Cultivation Procedures, which aim to produce 6,000 liters of Live Rosin per 100-acre farm per crop cycle. With 4-5 crop cycles per year, Pharmagreen projects revenues ranging from $19 million to $381 million in year 1, and $32 million to $635 million by year 3, depending on the price per gram. The company is seeking distributors and partnerships, and exploring the acquisition of a cGMP-certified cannabis lab in Europe. However, these projections depend on securing necessary licenses, permits, land leases, funding, and market access.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) has announced significant progress in its business development efforts, collaborating with a foreign government on a major project. The initiative aims to introduce Pharmagreen's proprietary Standard Organic Non-Spray Cultivation Procedures (SONSCP) to local farmers, promoting sustainable agriculture. The company plans to launch a premium, connoisseur-grade product line for the global market.
Pharmagreen reaffirms its commitment to non-toxic financing, with current operations funded by CEO Peter Wojcik. The company proposes a partnership structure to form a local subsidiary for project execution on a non-dilutive basis. Additionally, Pharmagreen's MaxGenomic® supplement is available on Amazon and the company's online store.
On February 8, 2023, Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) announced the successful development and online launch of its first formulated nutraceutical product, the MaxGenomic™ Supplement. This supplement, designed to assist DNA repair, features a blend of 15 natural ingredients from medicinal plants and mushrooms, packaged in delayed-release capsules. The company aims to penetrate the burgeoning nutraceutical market, valued in the hundreds of billions. Pharmagreen is collaborating with sports ambassador Tyrell Crosby for product promotion and plans to expand its product line to support active lifestyles. CEO Peter Wojcik emphasized expectations for revenue growth and enhanced shareholder value.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) has appointed NFL player Tyrell Crosby as an Honorary Sports Ambassador for its NutraMax Genomic Supplement line. Crosby will promote these products at events and online. The NutraMax supplement aims to support wellness through nutrigenomics, targeting stresses affecting health. The nutraceutical market is projected to grow to $750 billion by 2028. Pharmagreen is producing its first supply at a certified facility, ensuring quality with tested biomaterials. The team is optimistic about Crosby's endorsement driving brand awareness and growth.
Pharmagreen Biotech (OTCQB: PHBI) announces Ethan Styles as the new Vice President of Product Research and Development, bringing valuable expertise in therapeutic plants and molecular biology. Styles, a legacy cannabis cultivator, aims to expand Pharmagreen's focus beyond cannabis into a broader range of health products. His knowledge will aid in developing nutraceutical and protein-based formulations, enhancing the company's competitive edge. CEO Peter Wojcik highlights Styles as essential for fast-tracking revenues and shareholder value, aligning with the company's vision for wellness-oriented products.
Pharmagreen Biotech, Inc. (OTCQB: PHBI) has developed its first formulated nutraceutical product, a unique blend of 15 plant and mushroom ingredients aimed at DNA repair. The company is organizing retail distribution channels for this product, which will be available through an online store and platforms like Shopify and Amazon. The nutraceutical market is projected to grow from $449.5 billion in 2021 to $745.5 billion by 2028, with an annual growth of 8%. Additionally, Pharmagreen is advancing its cannabis business with Long Valley Farms and awaiting a micro business license to generate immediate revenue.
Pharmagreen Biotech, Inc. (OTCQB: PHBI) announces new cultivation efforts focusing on pharmaceutical plants and therapeutic fungi, leveraging proprietary tissue culture technologies. The company aims to generate near-term revenue from cannabis while developing nutraceuticals and supplements. Pharmagreen plans to launch an online store for its unique products and is processing a cannabis micro-business license for immediate revenue generation. The CEO emphasizes a focus on low-capital expenditures to drive revenue, with future plans for cannabis-based product sales.
Pharmagreen Biotech, Inc. (OTCQB: PHBI) has achieved a significant milestone in its collaboration with Long Valley Farms by advancing funds for securing essential micro-business and nursery licenses. This strategic move is expected to open up immediate revenue streams from the sale of live rosin and biomass to manufacturers and retailers. The daily revenue potential from live rosin production could reach up to $18K, supported by existing infrastructure and certifications. The company aims to enhance profitability through vertical integration and capitalizes on its expertise in the cannabis industry.
FAQ
What is the current stock price of PHARMAGREEN BIOTECH (PHBI)?
What is the market cap of PHARMAGREEN BIOTECH (PHBI)?
What does Pharmagreen Biotech Inc. specialize in?
Where is Pharmagreen Biotech Inc. headquartered?
What recent achievement has Pharmagreen Biotech Inc. made?
What is Pharmagreen Biotech Inc.'s long-term focus?
What is Pharmagreen Biotech Inc.'s innovative approach?
What are some of the products Pharmagreen Biotech Inc. is developing?
